Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CodeBreaK 201
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
- NCT04933695 ↗
- Terminated
- Amgen
- Focused
We haven't built an HCP commentary report on CodeBreaK 201 (sotorasib in first-line KRAS G12C stage IV NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CodeBreaK 201 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sotorasib
- Arms
- Sotorasib: 960 mg Daily · Experimental
- Sotorasib: 240 mg Daily · Experimental
- Enrollment
- 42
- Primary outcomes
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Amgen
- Start
- Jan 28, 2022
- Primary completion
- May 28, 2025
- Results posted
- Yes
- Registry record
- NCT04933695 · updated Jul 13, 2026